COMMUNIQUÉS West-GlobeNewswire

Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
14/04/2026
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with approximately 4–5 million patients, with launch planned during 2026 QUVIVIQ® is approved through Taiwan’s Streamlined Review [...]
Transactions in connection with share buy-back program
14/04/2026
Company announcement no. 10 - 26 14 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
14/04/2026
Strategic partnership enables upskilling of Novo Nordisk’s workforce and places the company at the forefront of AI transformation in healthcare Novo Nordisk will integrate OpenAI's most advanced AI capabilities globally [...]
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
14/04/2026
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that triggers a personalized [...]
Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma
14/04/2026
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling access to accelerated and rolling review FDA clearance of IND [...]
PannTheraPi Announces Significant Clinical Development and Strategic Milestones
14/04/2026
Regulatory submission filed to initiate a Phase 2a trial of its drug candidate, PTI5803 in patients with focal cortical dysplasia (FCD), a rare and severe form of epilepsy PannTheraPi secures European patent covering [...]
Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026
14/04/2026
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total product sales rose by 51% [...]
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique
14/04/2026
PannTheraPi annonce des avancées majeures dans son développement clinique et stratégique Le dépôt du dossier réglementaire pour l’initiation de l’essai clinique de Phase 2a évaluant son candidat médicament, PTI5803, [...]
Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
14/04/2026
MST-0312 is a FAP-targeted lymphotoxin beta receptor (LTBR) agonist bispecific antibody designed to induce tertiary lymphoid structures for the treatment of solid tumors CAMBRIDGE, United Kingdom, April 14, 2026 (GLOBE [...]
Rapid Nutrition Strengthens Capital Markets Infrastructure with Appointment of Bowsprit Partners
14/04/2026
LONDON, April 13, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech and wellness company focused on evidence-based nutrition brands and technology-enabled wellness solutions, is [...]
Vital Step GLP-1 Claims Evaluated: Trusted Doctor-Prescribed GLP-1 Weight Loss Medication with No Hidden Fees
14/04/2026
A 2026 program overview covering how Vital Step structures its doctor-prescribed compounded semaglutide and tirzepatide programs, monthly pricing, prescription access, and what adults considering medically supervised [...]
GloraMD Face Lift Serum Claims Evaluated: Liquid Anti-Aging Wrinkle Serum Solution for Skin Renewal
14/04/2026
A GloraMD Product Overview: Peptide Ingredients, Wrinkle Reduction Positioning, Anti-Aging Serum Formula Details, and Consumer Information for 2026 Los Angeles, April 13, 2026 (GLOBE NEWSWIRE) -- Affiliate Disclosure: [...]
Elite Force XL Male Enhancement Gummies Claims Evaluated: Effective Men's Formula for Steel Power Support
14/04/2026
A 2026 informational overview of Elite Force XL's male performance gummy formula, testosterone support positioning, ingredient category context, and what men seeking steel power should verify before purchasing New York [...]
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
13/04/2026
NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving [...]
Sana Biotechnology and Mayo Clinic Announce Strategic Collaboration Focused on Improving Care in Type 1 Diabetes and Accelerating Development of SC451
13/04/2026
Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patients with type 1 diabetes Initial efforts will include processes [...]
Celldex to Present at Upcoming Investor Conference
13/04/2026
HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on [...]
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
13/04/2026
EMERYVILLE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases [...]
Les données intermédiaires de l'essai pivot testant cema-cel mettent en évidence la solidité de la plateforme CAR-T allogénique de Cellectis
13/04/2026
NEW YORK, 13 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
13/04/2026
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]

Pages